In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long COVID following infection in previously vaccinated individuals.
Click arrow to play
Download TWiV 840 (55 MB .mp3, 46 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Show notes at microbe.tv/twiv
3 thoughts on “TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin”
Why is it that Covid Hospitalization Reports do not identify cases by vax and non vax?
Thanks for shaing this update. Hope we can get rid of COVID-19 finally.
Pingback: TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin - Virology Hub
Comments are closed.